{"id":10126,"date":"2026-06-07T00:24:12","date_gmt":"2026-06-06T21:24:12","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10126"},"modified":"2026-06-07T00:24:12","modified_gmt":"2026-06-06T21:24:12","slug":"single-versus-dual-antiplatelet-therapy-after-tavr-in-patients-without-an-indication-for-oral-anticoagulation","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/single-versus-dual-antiplatelet-therapy-after-tavr-in-patients-without-an-indication-for-oral-anticoagulation\/","title":{"rendered":"Single Versus Dual Antiplatelet Therapy After TAVR in Patients Without an Indication for Oral Anticoagulation"},"content":{"rendered":"<p><span>Single Versus Dual Antiplatelet Therapy After TAVR in Patients Without an Indication for Oral Anticoagulation<\/span><\/p>\n<p><span>TRITAVI Registry | JACC: Advances | 27 May 2026<\/span><\/p>\n<p><span>Take-Home Messages:<\/span><\/p>\n<p><span>In more than 5,000 TAVR patients without an indication for anticoagulation, SAPT improved survival without increasing stroke risk.<\/span><\/p>\n<p><span>SAPT reduced all-cause mortality:<\/span><br \/>\n<span>2.4% vs 5.4% at 6 months<\/span><br \/>\n<span>11.7% vs 14.2% at 24 months<\/span><\/p>\n<p><span>Major bleeding was less frequent with SAPT.<\/span><\/p>\n<p><span>Stroke and other ischemic events were similar between SAPT and DAPT.<\/span><\/p>\n<p><span>Use of DAPT declined over time as clinical practice shifted toward SAPT.<\/span><br \/>\n<a href=\"https:\/\/www.jacc.org\/doi\/10.1016\/j.jacadv.2026.102772\" target=\"_blank\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.jacc.org\/doi\/10.1016\/j.jacadv.2026.102772&amp;source=gmail&amp;ust=1780867335286000&amp;usg=AOvVaw1c0iUpNa8UWzcU7usjmuoN\" rel=\"noopener\">https:\/\/www.jacc.org\/doi\/10.<wbr \/>1016\/j.jacadv.2026.102772<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Single Versus Dual Antiplatelet Therapy After TAVR in Patients Without an Indication for Oral Anticoagulation TRITAVI Registry | JACC: Advances | 27 May 2026 Take-Home Messages: In more than 5,000 TAVR patients without an indication for anticoagulation, SAPT improved survival without increasing stroke risk. SAPT reduced all-cause mortality: 2.4% vs 5.4% at 6 months 11.7% [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10126","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10126"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10126\/revisions"}],"predecessor-version":[{"id":10127,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10126\/revisions\/10127"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}